Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine vs sufentanil for multimodal analgesia after gynecologic open tumor surgery under ERAS
ChiCTR2600116447Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tegileridine in Female reproductive system neoplasms (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Gastrointestinal motility score. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
Female reproductive system neoplasms
Beyond the preview
Go deeper on ChiCTR2600116447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116447.